

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 May 2020 (14.05.2020)



(10) International Publication Number
WO 2020/097265 A1

(51) International Patent Classification:

A61P 21/00 (2006.01)	C07D 405/04 (2006.01)
A61P 25/16 (2006.01)	C07D 405/12 (2006.01)
C07D 237/14 (2006.01)	C07D 405/14 (2006.01)
C07D 401/04 (2006.01)	C07D 413/12 (2006.01)
C07D 401/06 (2006.01)	C07D 491/107 (2006.01)
C07D 401/12 (2006.01)	C07D 495/10 (2006.01)
C07D 401/14 (2006.01)	C07D 498/08 (2006.01)
C07D 403/04 (2006.01)	A61K 31/50 (2006.01)
C07D 403/06 (2006.01)	A61K 31/501 (2006.01)
C07D 403/12 (2006.01)	

(21) International Application Number:

PCT/US2019/060155

(22) International Filing Date:

06 November 2019 (06.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/756,539 06 November 2018 (06.11.2018) US

(71) Applicant: **EDGEWISE THERAPEUTICS, INC.**
[US/US]; 3415 Colorado Avenue, Boulder, Colorado 80303
(US).

(72) Inventors: **HUNT, Kevin**; 3415 Colorado Avenue, Boul-
der, Colorado 80303 (US). **KOCH, Kevin**; 3415 Colorado
Avenue, Boulder, Colorado 80303 (US). **RUSSELL, Alan**;
3415 Colorado Avenue, Boulder, Colorado 80303 (US).
SCHLACHTER, Stephen; 3415 Colorado Avenue, Boul-
der, Colorado 80303 (US). **WINSHIP, Paul**; 251 Bal-

lardvale Street, Wilmington, MA 01887 (US). **STEELE, Chris**; 251 Ballardvale Street, Wilmington, MA 01887
(US). **UZOHO, Grace**; 251 Ballardvale Street, Wilming-
ton, MA 01887 (US).

(74) Agent: **MARGULIEUX, Grant W.**; Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali-
fornia 94304-1050 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: PYRIDAZINONE COMPOUNDS AND USES THEREOF




FIGURE 6

(57) Abstract: Substituted pyridazinone compounds, conjugates, and phar-
maceutical compositions for use in the treatment of neuromuscular diseases,
such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The
disclosed compounds are useful, among other things, in the treating of DMD
and modulating inflammatory inhibitors IL-1, IL-6 or TNF-.

[Continued on next page]

WO 2020/097265 A1

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*